Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2025 Filed Apr 2, 2025 21:40 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
GrantRestricted Stock Units · Derivative | 40,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · derivative · entry 4 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,295 Underlying: Common Stock · 40,295 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:40 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
GrantStock Option (right to buy) · Derivative | 198,019 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,019 Underlying: Common Stock · 198,019 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F3 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:40 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Tax withholdingCommon Stock | 3,172 | $14.51 | $46,025.72 |
DisclosureSEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,380.355 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:40 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionCommon Stock | 8,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000012 · wk-form4_1743630049.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,552.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 7,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 11 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,754 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F7 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F7 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 12,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 10 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,047 Underlying: Common Stock · 12,046 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 15,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 9 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,142 Underlying: Common Stock · 15,070 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 64,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 8 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,640 Underlying: Common Stock · 64,640 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 317,656 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 7 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,656 Underlying: Common Stock · 317,656 shares Expires not disclosed F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 3,819 | $14.51 | $55,413.69 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 6 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,084 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 7,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 5 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 5,933 | $14.51 | $86,087.83 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,149 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 12,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 7,422 | $14.51 | $107,693.22 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,036 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 15,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 3,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 11 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,579 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F7 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F7 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 10 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,555 Underlying: Common Stock · 6,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 9 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,401 Underlying: Common Stock · 8,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
GrantRestricted Stock Units · Derivative | 36,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 8 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,937 Underlying: Common Stock · 36,937 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
GrantStock Option (right to buy) · Derivative | 181,518 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · derivative · entry 7 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,518 Underlying: Common Stock · 181,518 shares Expires not disclosed F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 1,763 | $14.51 | $25,581.13 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 6 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,230.614 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 3,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 5 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,993.614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 2,645 | $14.51 | $38,378.95 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,414.614 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,059.614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 2,809 | $14.51 | $40,758.59 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,504.614 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:43 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000016 · wk-form4_1743630181.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,313.614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionRestricted Stock Units · Derivative | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 14 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F8 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F8 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionRestricted Stock Units · Derivative | 4,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 13 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,861 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F7 · derivative.exercise_date: On November 7, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F7 · derivative.expiration_date: On November 7, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionRestricted Stock Units · Derivative | 11,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 12 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,338 Underlying: Common Stock · 11,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionRestricted Stock Units · Derivative | 14,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 11 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,369 Underlying: Common Stock · 14,184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
GrantRestricted Stock Units · Derivative | 20,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 10 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,147 Underlying: Common Stock · 20,147 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
GrantStock Option (right to buy) · Derivative | 99,009 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 9 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,009 Underlying: Common Stock · 99,009 shares Expires not disclosed F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Tax withholdingCommon Stock | 1,346 | $14.51 | $19,530.46 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 8 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,169.46 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionCommon Stock | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 7 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,515.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Tax withholdingCommon Stock | 1,524 | $14.51 | $22,113.24 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 6 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,221.46 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionCommon Stock | 4,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 5 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,745.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Tax withholdingCommon Stock | 3,554 | $14.51 | $51,568.54 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 4 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,884.46 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionCommon Stock | 11,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 3 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,438.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Tax withholdingCommon Stock | 4,446 | $14.51 | $64,511.46 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 2 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,100.46 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionCommon Stock | 14,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,546.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 3,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · derivative · entry 11 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,579 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F7 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F7 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · derivative · entry 10 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,732 Underlying: Common Stock · 6,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · derivative · entry 9 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,844 Underlying: Common Stock · 8,421 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
GrantRestricted Stock Units · Derivative | 33,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · derivative · entry 8 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,579 Underlying: Common Stock · 33,579 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
GrantStock Option (right to buy) · Derivative | 165,016 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · derivative · entry 7 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,016 Underlying: Common Stock · 165,016 shares Expires not disclosed F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 1,763 | $14.51 | $25,581.13 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · nonDerivative · entry 6 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,473.661 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 3,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · nonDerivative · entry 5 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,236.661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 2,591 | $14.51 | $37,595.41 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · nonDerivative · entry 4 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,657.661 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · nonDerivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,248.661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 8,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000020 · wk-form4_1743630305.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,401.661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.